Treating periodontal diseases by blocking tissue-destructive enzymes.
A new therapeutic approach involves the discovery by the "Stony Brook group," that tetracyclines, but not other antibiotics, can inhibit host-derived collagen-destructive enzymes. This newly discovered property of tetracyclines is unrelated to the antimicrobial activity of these drugs. Examples support the hypothesis that this unexpected property of tetracyclines provides a new approach to treating periodontal diseases as well as a variety of medical disorders.
Golub
L M
LM
Department of Oral Biology and Pathology, School of Dental Medicine, SUNY at Stony Brook 11794-8700.
Wolff
M
M
Roberts
S
S
Lee
H M
HM
Leung
M
M
Payonk
G S
GS
D005883:Gingival Crevicular Fluid / Q000201:enzymology; D061965:Matrix Metalloproteinase Inhibitors; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D010510:Periodontal Diseases / Q000188:drug therapy* / Q000201:enzymology*; D010514:Periodontal Pocket / Q000201:enzymology; D013752:Tetracycline / Q000627:therapeutic use; D013754:Tetracyclines / Q000627:therapeutic use*
D061965:Matrix Metalloproteinase Inhibitors; D013754:Tetracyclines; C053450:4-des-dimethylaminotetracycline; D008666:Metalloendopeptidases; D013752:Tetracycline